Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments

Tuberculosis

Volumn 95, Issue 6, 2015, Pages 770-779

  Kayigire, Xavier A ^a,b   Friedrich, Sven O ^a,b   Van Der Merwe, Lize ^c   Donald, Peter R ^a   Diacon, Andreas H ^a,b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b TASK APPLIED SCIENCE   (South Africa)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Dormancy; Fluorescence microscopy; Mycobacterium tuberculosis; Rifampicin

Indexed keywords

AGAR; AURAMINE; LIPID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; RIFAMPICIN; ADAMANTANE; ETHYLENEDIAMINE DERIVATIVE; FAT DROPLET; FLUORESCENT DYE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; NILE RED; OXAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; ARTICLE; CELL COUNTING; CLINICAL ARTICLE; CLINICAL EVALUATION; COLONY FORMING UNIT; CONFOCAL LASER MICROSCOPY; HUMAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BACTERIAL COUNT; BACTERIAL LOAD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFECTS; DRUG MONITORING; FLUORESCENCE MICROSCOPY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; SPUTUM; TIME FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADAMANTANE; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; BENZOPHENONEIDUM; COLONY COUNT, MICROBIAL; DRUG MONITORING; DRUG THERAPY, COMBINATION; ETHYLENEDIAMINES; FLUORESCENT DYES; HUMANS; LIPID DROPLETS; MICROSCOPY, FLUORESCENCE; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; PREDICTIVE VALUE OF TESTS; RIFAMPIN; SOUTH AFRICA; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84948714237     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2015.08.001     Document Type: Article

References (50)

1. J. Bigger Treatment of staphylococcal infections with penicillin by intermittent sterilisation Lancet 244 6320 1944 497 500
2. C. Wiuff, R.M. Zappala, R.R. Regoes, K.N. Garner, F. Baquero, and B.R. Levin Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations Antimicrob Agents Chemother 49 4 2005 1483 1494
3. G.L. Hobby, O. Auerbach, T.F. Lenert, M.J. Small, and J.V. Comer The late emergence of M. Tuberculosis in liquid cultures of pulmonary lesions resected from humans Am Rev Tuberc 70 2 1954 191 218
4. W. McDermott, R.M. McCune Jr.; and R. Tompsett Dynamics of antituberculous chemotherapy Am Rev Tuberc 74 2 Part 2 1956 100 108
5. R.O. Loebel, E. Shorr, and H.B. Richardson The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli J Bacteriol 26 2 1933 167 200
6. C. Deb, C.M. Lee, V.S. Dubey, J. Daniel, B. Abomoelak, T.D. Sirakova, S. Pawar, L. Rogers, and P.E. Kolattukudy A novel in vitro multiple-stress dormancy model for mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen PLoS One 4 6 2009 e6077
7. T. Hampshire, S. Soneji, J. Bacon, B.W. James, J. Hinds, K. Laing, R.A. Stabler, P.D. Marsh, and P.D. Butcher Stationary phase gene expression of mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis 84 3 2004 228 238
8. L.G. Wayne, and L.G. Hayes An in vitro model for sequential study of shiftdown of mycobacterium tuberculosis through two stages of nonreplicating persistence Infect Immun 64 6 1996 2062 2069
9. L.G. Wayne, and C.D. Sohaskey Nonreplicating persistence of mycobacterium tuberculosis Annu Rev Microbiol 55 2001 139 163
10. T. Lillebaek, A. Dirksen, E. Vynnycky, I. Baess, V.O. Thomsen, and A.B. Andersen Stability of DNA patterns and evidence of mycobacterium tuberculosis reactivation occurring decades after the initial infection J Infect Dis 188 7 2003 1032 1039
11. T.R. Rustad, A.M. Sherrid, K.J. Minch, and D.R. Sherman Hypoxia: a window into mycobacterium tuberculosis latency Cell Microbiol 11 8 2009 1151 1159
12. C. Larsson, B. Luna, N.C. Ammerman, M. Maiga, N. Agarwal, and W.R. Bishai Gene expression of mycobacterium tuberculosis putative transcription factors whiB1-7 in redox environments PloS One 7 7 2012 e37516
13. J. Daniel, H. Maamar, C. Deb, T.D. Sirakova, and P.E. Kolattukudy Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages PLoS Pathog 7 6 2011 e1002093
14. J.E. Gomez, and J.D. McKinney M. Tuberculosis persistence, latency, and drug tolerance Tuberc (Edinb) 84 1-2 2004 29 44
15. J. Dhillon, P.B. Fourie, and D.A. Mitchison Persister populations of mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media J Antimicrob Chemother 69 2 2014 437 440
16. M. Shleeva, G.V. Mukamolova, M. Young, H.D. Williams, and A.S. Kaprelyants Formation of 'non-culturable' cells of mycobacterium smegmatis in stationary phase in response to growth under suboptimal conditions and their rpf-mediated resuscitation Microbiology 150 Pt 6 2004 1687 1697
17. G.V. Mukamolova, O. Turapov, J. Malkin, G. Woltmann, and M.R. Barer Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum Am J Respir Crit Care Med 181 2 2010 174 180
18. P. Seiler, T. Ulrichs, S. Bandermann, L. Pradl, S. Jorg, V. Krenn, L. Morawietz, S.H. Kaufmann, and P. Aichele Cell-wall alterations as an attribute of mycobacterium tuberculosis in latent infection J Infect Dis 188 9 2003 1326 1331
19. G.J. Domingue Demystifying pleomorphic forms in persistence and expression of disease: are they bacteria, and is peptidoglycan the solution? Discov Med 10 52 2010 234 246
20. N.J. Garton, H. Christensen, D.E. Minnikin, R.A. Adegbola, and M.R. Barer Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum Microbiology 148 Pt 10 2002 2951 2958
21. N.J. Garton, S.J. Waddell, A.L. Sherratt, S.M. Lee, R.J. Smith, C. Senner, J. Hinds, K. Rajakumar, R.A. Adegbola, G.S. Besra, P.D. Butcher, and M.R. Barer Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum PLoS Med 5 4 2008 e75
22. A. Jindani, V.R. Aber, E.A. Edwards, and D.A. Mitchison The early bactericidal activity of drugs in patients with pulmonary tuberculosis Am Rev Respir Dis 121 6 1980 939 949
23. A.H. Diacon, and P.R. Donald The early bactericidal activity of antituberculosis drugs Expert Rev Anti Infect Ther 12 2 2014 223 237
24. P. Donald, and A. Diacon The early bactericidal activity of anti-tuberculosis drugs: a literature review Tuberculosis 88 2008 S75 S83
25. P. Phillips, and K. Fielding Surrogate markers for poor outcome to treatment for tuberculosis: results from extensive multi-trial analysis Int J Tuberc Lung Dis 12 Suppl. 2 2008 S146 S147
26. Z. Taylor, C.M. Nolan, and H.M. Blumberg American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American thoracic society, CDC, and the infectious diseases society of America MMWR Recomm Rep 54 RR-12 2005 1 81
27. S.H. Gillespie, A.M. Crook, T.D. McHugh, C.M. Mendel, S.K. Meredith, S.R. Murray, F. Pappas, P.P. Phillips, and A.J. Nunn Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis N Engl J Med 371 17 2014 1577 1587
28. A. Jindani, T.S. Harrison, A.J. Nunn, P.P. Phillips, G.J. Churchyard, S. Charalambous, M. Hatherill, H. Geldenhuys, H.M. McIlleron, and S.P. Zvada High-dose rifapentine with moxifloxacin for pulmonary tuberculosis N Engl J Med 371 17 2014 1599 1608
29. C.S. Merle, K. Fielding, O.B. Sow, M. Gninafon, M.B. Lo, T. Mthiyane, J. Odhiambo, E. Amukoye, B. Bah, and F. Kassa A four-month gatifloxacin-containing regimen for treating tuberculosis N Engl J Med 371 17 2014 1588 1598
30. N. Heinrich, R. Dawson, J. du Bois, K. Narunsky, G. Horwith, A.J. Phipps, C.A. Nacy, R.E. Aarnoutse, M.J. Boeree, S.H. Gillespie, A. Venter, S. Henne, A. Rachow, P.P. Phillips, M. Hoelscher, A.H. Diacon on behalf of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients J Antimicrob Chemother 70 5 2015 1558 1566
31. A.M. Anuchin, A.L. Mulyukin, N.E. Suzina, V.I. Duda, G.I. El-Registan, and A.S. Kaprelyants Dormant forms of mycobacterium smegmatis with distinct morphology Microbiology 155 Pt 4 2009 1071 1079
32. M.O. Shleeva, Y.K. Kudykina, G.N. Vostroknutova, N.E. Suzina, A.L. Mulyukin, and A.S. Kaprelyants Dormant ovoid cells of mycobacterium tuberculosis are formed in response to gradual external acidification Tuberc (Edinb) 91 2 2011 146 154
33. M. Krzywinski, and N. Altman Points of significance: visualizing samples with box plots Nat Methods 11 2 2014 119 120
34. J.M. Chambers, W.S. Cleveland, B. Kleiner, and P.A. Tukey Graphical methods for data analysis 1983 Wadsworth & Brooks Pacific Grove, California 82 87
35. J. Pinheiro, D. Bates, S. DebRoy, D. Sarkar R Core Team nlme: linear and nonlinear mixed effects models 2014 R package version 3.1-117 http://Cran.R-Project.Org/Web/Packages/Nlme/Index.Html
36. A. Diacon, R. Dawson, M. Hanekom, K. Narunsky, A. Venter, N. Hittel, L. Geiter, C. Wells, A. Paccaly, and P. Donald Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients Int J Tuberc Lung Dis 15 7 2011 949 954
37. D. Mitchison Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months Am Rev Respir Dis 147 4 1993 1062 1063
38. Y. Zhang Persisters, persistent infections and the Yin-Yang model Emerg Microbes Infect 3 1 2014 e3
39. J.C. Leemans, N.P. Juffermans, S. Florquin, N. van Rooijen, M.J. Vervoordeldonk, A. Verbon, S.J. van Deventer, and T. van der Poll Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice J Immunol 166 7 2001 4604 4611
40. N. Dhar, and J.D. McKinney Microbial phenotypic heterogeneity and antibiotic tolerance Curr Opin Microbiol 10 1 2007 30 38
41. L.E. Connolly, P.H. Edelstein, and L. Ramakrishnan Why is long-term therapy required to cure tuberculosis? PLoS Med 4 3 2007 e120
42. D.J. Sloan, H.C. Mwandumba, N.J. Garton, S.H. Khoo, A.E. Butterworth, T.J. Allain, R.S. Heyderman, E.L. Corbett, M.R. Barer, and G.R. Davies Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis Clin Infect Dis 61 1 2015 1 8
43. R.M. McCune Jr.; and R. Tompsett Fate of mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. the persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy J Exp Med 104 5 1956 737 762
44. K.N. Adams, K. Takaki, L.E. Connolly, H. Wiedenhoft, K. Winglee, O. Humbert, P.H. Edelstein, C.L. Cosma, and L. Ramakrishnan Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism Cell 145 1 2011 39 53
45. L. Jia, J.E. Tomaszewski, C. Hanrahan, L. Coward, P. Noker, G. Gorman, B. Nikonenko, and M. Protopopova Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug Br J Pharmacol 144 1 2005 80 87
46. B.V. Nikonenko, M. Protopopova, R. Samala, L. Einck, and C.A. Nacy Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs Antimicrob Agents Chemother 51 4 2007 1563 1565
47. R.S. Wallis, W. Jakubiec, M. Mitton-Fry, L. Ladutko, S. Campbell, D. Paige, A. Silvia, and P.F. Miller Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide PLoS One 7 1 2012 e30479
48. B.W. Kwan, J.A. Valenta, M.J. Benedik, and T.K. Wood Arrested protein synthesis increases persister-like cell formation Antimicrob Agents Chemother 57 3 2013 1468 1473
49. P. Chen, J. Gearhart, M. Protopopova, L. Einck, and C.A. Nacy Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro J Antimicrob Chemother 58 2 2006 332 337
50. K.A. Sacksteder, M. Protopopova, C.E. Barry, K. Andries, and C.A. Nacy Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action Future Microbiol 7 7 2012 823 837